drugset / Trial / NCT03597971
HMPL004-6599 Phase I Dose-escalating Study
Phase 1
Terminated
32 enrolled
Nutrition Science Partners Limited
Hutchison Medipharma Limited · collabSociété des Produits Nestlé (SPN) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
To assess the safety and tolerability of single and multiple doses of HMPL004-6599 in healthy male volunteers
Timeline
- Start
- 2018-03-20
- Primary completion
- 2018-11-19
- Completion
- 2018-11-19
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HMPL004-6599 | Unknown | 200 mg | — |
| Subject | HMPL004-6599 | Unknown | 400 mg | — |
| Subject | HMPL004-6599 | Unknown | 600 mg | — |
| Subject | HMPL004-6599 | Unknown | 1200 mg | — |
| Subject | HMPL004-6599 | Unknown | 1800 mg | — |